Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review

Malvi Savani, Katti Woerner, Lihong Bu, Mark P Birkenbach, Keith M. Skubitz

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Doxorubicin is one of the most active drugs for sarcoma. Pegylated liposomal doxorubicin (PLD) is a unique formulation of doxorubicin, which carries a more favorable toxicity profile in comparison with free doxorubicin. The main toxicity of PLD is hand–foot syndrome. Unlike free doxorubicin, PLD is unlikely to cause alopecia, nausea, myelosuppression, or cardiotoxicity. Additionally, no premedications are required. We describe the case of a 50-year-old man with advanced retroperitoneal liposarcoma who developed irreversible PLD-associated progressive renal failure requiring chronic hemodialysis due to a thrombotic microangiopathy. No cardiotoxicity was noted 84 months after he initiated PLD. This case describes a lesser known toxicity of PLD and may be a toxicity of long-term treatment with other liposomal drugs.

Original languageEnglish (US)
Pages (from-to)289-294
Number of pages6
JournalCancer chemotherapy and pharmacology
Volume87
Issue number2
DOIs
StatePublished - Feb 2021

Bibliographical note

Publisher Copyright:
© 2021, Springer-Verlag GmbH Germany, part of Springer Nature.

Keywords

  • Doxorubicin
  • Renal toxicity
  • Sarcoma

PubMed: MeSH publication types

  • Case Reports
  • Journal Article
  • Review

Fingerprint

Dive into the research topics of 'Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review'. Together they form a unique fingerprint.

Cite this